Presentations – 20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs

Tuesday 14 MayWednesday 15 MayThursday 16 May
 

Tuesday 14 May

  Session 1 - 20 Years in Review
Chairs: David Burger & David Back
 
 

Drug-drug interactions: all you need to know beyond www.hiv-druginteractions.org
Marta Boffito, MD, PhD - Chelsea and Westminster Hospital, United Kingdom

 
 

Courtney Fletcher, PharmDStop measuring ARV levels in plasma!
No permission to publish slides or video
Courtney Fletcher, PharmD - University of Nebraska, United States

 
 

Terrence Blaschke, MD

50% adherence is enough with modern ARVs, right?
Terrence Blaschke, MD - Stanford University, United States

 

from Virology Education on Vimeo.

 
 

Jonathan Schapiro, MDModern ARVs do not develop resistance, do they?
No permission to publish slides or video
Jonathan Schapiro, MD - Sheba Medical Center, Israel

 
   
 

Wednesday 15 May

 Session 2 - Novel strategies for prevention and therapy
Chairs: Andrea Calcagno & Kimberly Scarsi
 

The ‘third wave’ of TB drug development: what’s on the horizon (for patients with or without HIV)
Kelly Dooley, MD, PhD - Johns Hopkins University, United States

 

from Virology Education on Vimeo.

 
 Abstract-driven Presentations
Note: Videos are not available for abstract-driven presentations
 

Efavirenz pharmacokinetics in HIV/TB coinfected persons initiating ART while receiving high dose rifapentine
Anthony Podany, PharmD - University of Nebraska Medical Center, United States

 #1
 In silico design of a microarray patch as a multipurpose prevention technology
Rajith Rajoli - Univerisity Of Liverpool, United Kingdom

 #2
 Population pharmacokinetics of VRC01 in infants and adults
Jerry Li - University of California San Diego, United States
 #3
 The initial Phase 1 evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next generation HIV maturation inhibitor, as assessed in healthy subjects
Samit Joshi, MD - ViiV Healthcare, United States
 #4
   
 Session 3 - Viral Hepatitis & Liver Disease
Chairs: Jennifer Kiser & Alice Tseng 
 

Novel antiviral and immune targets to cure HBV
Fabien Zoulim, MD - INSERM, France

 

from Virology Education on Vimeo.

 
 

Pharmacological treatment of NASH
Sven Francque, MD, PhD - University Hospital Antwerp & University of Antwerp, Belgium

 

from Virology Education on Vimeo.

 
 Special Session: Improving drug delivery for sustained treatment success - Supported by ViiV Healthcare
Chair: Jonathan Schapiro
 
 

Improved long acting drug delivery: What are the technologies?
Andrew Owen, BSc, MSc, PhD, FSB - University of Liverpool, United Kingdom

 

from Virology Education on Vimeo.

 
 

Long acting HIV drugs for treatment: Data and potential implementation
Charles Flexner, MD - Johns Hopkins University, United States

 

from Virology Education on Vimeo.

 
 

Long Acting HIV Drugs for Prevention: Data and Potential implementation
Laura Waters, MD - Central & North West London NHS Trust, Mortimer Market Centre, United Kingdom

 

from Virology Education on Vimeo.

 
   
 Session 4 - Drug-drug interactions: evolving challenges
Chairs: Saye Khoo & Angela Kashuba
 

Clinical Case Presentation
Catia Marzolini, PharmD, PhD - University Hospital Basel & University of Liverpool

 

from Virology Education on Vimeo.

 
 

ClinicalCasesDDI Website Launch
No permission to publish slides or video
José Moltó, MD, PhD - Hospital Universitari Germans Trias i Pujol, Spain

 
 Abstract-driven Presentations
Note: Videos are not available for abstract-driven presentations
 Changes in drug interaction profiles for first-line HIV therapy over the 20 years of the Liverpool Drug Interaction website
Sara Gibbons - University of Liverpool, United Kingdom
 #5
 Drugs abuse and chemsex: a new challenge for antiretroviral drug-drug interaction
Tess Martin - APHM La Timone, France
 #6
 Effect of CYP2b6 metabolizer status on levonorgestrel pharmacokinetics when combined with efavirenz-based antiretroviral therapy
Michelle Pham - University Of Nebraska Medical Center
 #7
   
 Debate: Dual maintenance for HIV: Why fix it if it's not broken?
Moderator: Jonathan Schapiro
 
 

Pro Perspective
José Ramón Arribas, MD - Hospital La Paz, IdiPaz, Spain

 

from Virology Education on Vimeo.

 
 

Con Perspective
Andrew Hill, MD - University of Liverpool, United Kingdom

 

from Virology Education on Vimeo.

 
 

Debate

 

from Virology Education on Vimeo.

 
 Special Lecture
 Regulatory perspective on evaluating ARVs in during pregnancy
No permission to publish slides or video
Kimberly Struble, PharmD - US Food & Drug Administration, United States
 
   
 

Thursday 16 May

 Session 5 - Special populations and adherence
Chairs: Terrence Blaschke & Tim Cressey
Note: Videos are not available for abstract-driven presentations
 Special Presentation: Infectious disease action plan for the global accelerator for paediatric formulations (GAP-f)
Paul Domanico, PhD - Clinton Health Access Initiative, United States
 #8
 Infant exposure to dolutegravir through placental and breastmilk transfer: A population PK analysis of DolPHIN-1
Laura Dickinson - University Of Liverpool, United Kingdom
 #9
 Pharmacokinetics of atazanavir boosted with cobicistat during pregnancy and postpartum
Jeremiah Momper - University Of California San Diego, United States
 #10
 Low isoniazid concentrations in pregnant and postpartum women treated for tuberculosis irrespective of efavirenz-based ART co-treatment
Marije Van Schalkwyk, MD - Stellenbosch University, South Africa
 #11
 Pharmacokinetics of tenofovir alafenamide 25 mg with PK boosters during pregnancy and postpartum
Kristina Brooks, PharmD - University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, United States
 #12
 Tenofovir-diphosphate in PBMC following increasing TAF vs. TDF dosing under directly observed therapy
Jenna Yager - University of Colorado, United States
 #13
 An exploration of adherence measures to detect recent changes in Truvada® dosing patterns
Daijha Anderson - University Of North Carolina Eshelman School Of Pharmacy, United States
 #14
   
 Short Poster Presentations; "Best of Posters"
Moderator: Giovanni Di Perri & Marco Siccardi
Note: Videos are not available for poster-driven presentations
 Physiologically based pharmacokinetic modelling to determine pharmacokinetic alterations driving ritonavir exposure changes in aging people living with HIV
Felix Stader, University Hospital Basel, Switzerland
 #15
 Physiologically-based pharmacokinetic modeling of rilpivirine during pregnancy
Mary Gockenbach - US Food and Drug Administration, Division of Pediatrics and Maternal Health
 #16
 A semi-mechanistic population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: A study of HIV-infected Zimbabwean adolescents
(Not yet available)

Bernard Ngara - University Of Zimbabwe College Of Health Sciences, Zimbabwe
 #17
 Utilization of physiologically based pharmacokinetic modelling (PBPK) to predict the effect of UGT enzyme inhibition and induction on the systemic exposure of Cabotegravir
Aarti Patel - Glaxosmithkline R&D, United Kingdom
 #18
 The Next 20 Years
Chairs: Charles Flexner & David Burger
 

CRISPR/Cas and gene editing for HIV
Paula Cannon, PhD - University of Southern California Keck School of Medicine, United States

 

from Virology Education on Vimeo.

 
 

Owen, Andrew - 2019Understanding the key determinants of performance for long-acting formulations
No permission to publish slides or video
Andrew Owen, BSc, MSc, PhD, FSB - University of Liverpool, United Kingdom